Filing Details

Accession Number:
0001567619-21-017751
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-10-01 16:34:19
Reporting Period:
2021-09-29
Accepted Time:
2021-10-01 16:34:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1650648 4D Molecular Therapeutics Inc. FDMT Biological Products, (No Disgnostic Substances) (2836) 473506994
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1692929 David Schaffer C/O 4D Molecular Therapeutics Inc.
5858 Horton Street #455
Emeryville CA 94608
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-09-29 7,806 $27.99 958,950 No 4 S Direct
Common Stock Disposition 2021-09-29 8,365 $29.06 950,585 No 4 S Direct
Common Stock Disposition 2021-09-29 700 $30.06 949,885 No 4 S Direct
Common Stock Disposition 2021-09-30 7,836 $26.69 942,049 No 4 S Direct
Common Stock Disposition 2021-09-30 4,549 $27.28 937,500 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
  2. The transaction was executed in multiple trades in prices ranging from $27.70 to $28.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. The transaction was executed in multiple trades in prices ranging from $28.71 to $29.69, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  4. The transaction was executed in multiple trades in prices ranging from $29.75 to $30.66, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  5. The transaction was executed in multiple trades in prices ranging from $26.07 to $27.06, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  6. The transaction was executed in multiple trades in prices ranging from $27.08 to $27.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.